|
1
|
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
|
Lancet
|
2002
|
16.56
|
|
2
|
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.
|
Lancet
|
2009
|
14.01
|
|
3
|
Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study.
|
PLoS Pathog
|
2013
|
6.14
|
|
4
|
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals.
|
AIDS
|
2010
|
5.85
|
|
5
|
Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover.
|
J Exp Med
|
2007
|
5.58
|
|
6
|
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.
|
Ann Intern Med
|
2011
|
5.35
|
|
7
|
Comparison of dynamic treatment regimes via inverse probability weighting.
|
Basic Clin Pharmacol Toxicol
|
2006
|
5.25
|
|
8
|
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis.
|
Lancet
|
2006
|
5.00
|
|
9
|
Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men.
|
AIDS
|
2003
|
4.43
|
|
10
|
Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.
|
Lancet Oncol
|
2009
|
4.38
|
|
11
|
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies.
|
AIDS
|
2007
|
4.31
|
|
12
|
Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients.
|
J Clin Oncol
|
2003
|
4.15
|
|
13
|
Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS.
|
Int J Epidemiol
|
2004
|
3.99
|
|
14
|
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.
|
J Infect Dis
|
2005
|
3.52
|
|
15
|
Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic).
|
J Acquir Immune Defic Syndr
|
2008
|
3.44
|
|
16
|
Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey.
|
Clin Infect Dis
|
2009
|
3.28
|
|
17
|
Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol.
|
J Hepatol
|
2005
|
3.18
|
|
18
|
Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.
|
Cancer
|
2004
|
2.98
|
|
19
|
Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
|
J Clin Oncol
|
2006
|
2.82
|
|
20
|
Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries.
|
J Acquir Immune Defic Syndr
|
2014
|
2.79
|
|
21
|
HIV and coronary heart disease: time for a better understanding.
|
J Am Coll Cardiol
|
2013
|
2.78
|
|
22
|
Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy.
|
AIDS
|
2008
|
2.74
|
|
23
|
Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries.
|
Int J Epidemiol
|
2009
|
2.51
|
|
24
|
When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data.
|
Int J Biostat
|
2010
|
2.50
|
|
25
|
Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy.
|
AIDS
|
2009
|
2.50
|
|
26
|
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE).
|
PLoS Med
|
2013
|
2.49
|
|
27
|
Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir.
|
AIDS
|
2008
|
2.21
|
|
28
|
Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.
|
Arch Intern Med
|
2010
|
2.17
|
|
29
|
Clinically validated genotype analysis: guiding principles and statistical concerns.
|
Antivir Ther
|
2004
|
2.14
|
|
30
|
The undiagnosed HIV epidemic in France and its implications for HIV screening strategies.
|
AIDS
|
2014
|
2.04
|
|
31
|
Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression.
|
J Infect Dis
|
2005
|
2.03
|
|
32
|
Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial.
|
AIDS
|
2002
|
2.03
|
|
33
|
Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalité 2005 study.
|
J Hepatol
|
2009
|
1.98
|
|
34
|
Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA.
|
AIDS
|
2003
|
1.97
|
|
35
|
Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients.
|
AIDS
|
2009
|
1.93
|
|
36
|
Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population.
|
AIDS
|
2010
|
1.93
|
|
37
|
HIV infection in older patients in the HAART era.
|
J Antimicrob Chemother
|
2005
|
1.90
|
|
38
|
Risk of triple-class virological failure in children with HIV: a retrospective cohort study.
|
Lancet
|
2011
|
1.90
|
|
39
|
Observation plans in longitudinal studies with time-varying treatments.
|
Stat Methods Med Res
|
2008
|
1.89
|
|
40
|
Frequency, determinants and consequences of delayed access to care for HIV infection in France.
|
Antivir Ther
|
2007
|
1.83
|
|
41
|
Effect of early syphilis infection on plasma viral load and CD4 cell count in human immunodeficiency virus-infected men: results from the FHDH-ANRS CO4 cohort.
|
Arch Intern Med
|
2012
|
1.77
|
|
42
|
Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots.
|
J Clin Microbiol
|
2005
|
1.77
|
|
43
|
Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV.
|
AIDS
|
2009
|
1.74
|
|
44
|
Do tests devised to detect recent HIV-1 infection provide reliable estimates of incidence in Africa?
|
J Acquir Immune Defic Syndr
|
2007
|
1.68
|
|
45
|
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study.
|
Lancet Infect Dis
|
2011
|
1.68
|
|
46
|
Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV.
|
AIDS
|
2004
|
1.67
|
|
47
|
French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002.
|
J Acquir Immune Defic Syndr
|
2005
|
1.63
|
|
48
|
Predictors identified for losses to follow-up among HIV-seropositive patients.
|
J Clin Epidemiol
|
2006
|
1.63
|
|
49
|
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach.
|
Retrovirology
|
2009
|
1.58
|
|
50
|
Comparing the public health burden of chronic hepatitis C and HIV infection in France.
|
J Hepatol
|
2004
|
1.57
|
|
51
|
Twelve months of routine HIV screening in 6 emergency departments in the Paris area: results from the ANRS URDEP study.
|
PLoS One
|
2012
|
1.56
|
|
52
|
The incubation period of kuru.
|
Epidemiology
|
2002
|
1.56
|
|
53
|
Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients.
|
AIDS
|
2011
|
1.47
|
|
54
|
Imported malaria in HIV-infected patients enrolled in the ANRS CO4 FHDH study.
|
J Acquir Immune Defic Syndr
|
2008
|
1.46
|
|
55
|
Routine HIV screening in France: clinical impact and cost-effectiveness.
|
PLoS One
|
2010
|
1.46
|
|
56
|
No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients.
|
AIDS
|
2005
|
1.45
|
|
57
|
Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention.
|
Catheter Cardiovasc Interv
|
2011
|
1.44
|
|
58
|
Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America.
|
AIDS
|
2015
|
1.44
|
|
59
|
Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.
|
AIDS
|
2006
|
1.43
|
|
60
|
Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease.
|
J Exp Med
|
2005
|
1.43
|
|
61
|
Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy.
|
AIDS
|
2009
|
1.42
|
|
62
|
Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
|
AIDS
|
2006
|
1.42
|
|
63
|
Correlation between breadth of memory HIV-specific cytotoxic T cells, viral load and disease progression in HIV infection.
|
AIDS
|
2002
|
1.35
|
|
64
|
Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements.
|
AIDS
|
2009
|
1.32
|
|
65
|
Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
|
Antimicrob Agents Chemother
|
2003
|
1.31
|
|
66
|
Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion.
|
J Natl Cancer Inst
|
2010
|
1.31
|
|
67
|
Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013.
|
Euro Surveill
|
2015
|
1.29
|
|
68
|
AIDS-related malignancies: state of the art and therapeutic challenges.
|
J Clin Oncol
|
2008
|
1.28
|
|
69
|
High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors.
|
AIDS
|
2011
|
1.28
|
|
70
|
HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals.
|
Clin Infect Dis
|
2012
|
1.28
|
|
71
|
Clinically relevant interpretation of genotype for resistance to abacavir.
|
AIDS
|
2003
|
1.27
|
|
72
|
Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the french hospital database on HIV.
|
J Clin Oncol
|
2012
|
1.27
|
|
73
|
Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000.
|
AIDS
|
2014
|
1.27
|
|
74
|
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes.
|
J Acquir Immune Defic Syndr
|
2006
|
1.27
|
|
75
|
Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy.
|
PLoS One
|
2011
|
1.25
|
|
76
|
Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
|
Clin Infect Dis
|
2012
|
1.25
|
|
77
|
Low prevalence of HIV type 1 drug resistance mutations in untreated, recently infected patients from Burkina Faso, Côte d'Ivoire, Senegal, Thailand, and Vietnam: the ANRS 12134 study.
|
AIDS Res Hum Retroviruses
|
2009
|
1.25
|
|
78
|
HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis.
|
Blood
|
2011
|
1.25
|
|
79
|
Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France.
|
AIDS
|
2003
|
1.24
|
|
80
|
Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452).
|
AIDS
|
2008
|
1.23
|
|
81
|
Skin cancers associated with HIV infection and solid-organ transplantation among elderly adults.
|
Int J Cancer
|
2010
|
1.22
|
|
82
|
Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance.
|
J Med Virol
|
2006
|
1.22
|
|
83
|
Characteristics of B-cell lymphomas in HIV/HCV-coinfected patients during the combined antiretroviral therapy era: an ANRS CO16 LYMPHOVIR cohort study.
|
J Acquir Immune Defic Syndr
|
2013
|
1.18
|
|
84
|
Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients.
|
J Infect
|
2006
|
1.18
|
|
85
|
Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
|
Antimicrob Agents Chemother
|
2004
|
1.16
|
|
86
|
A therapeutic dendritic cell-based vaccine for HIV-1 infection.
|
J Infect Dis
|
2011
|
1.15
|
|
87
|
Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients.
|
Antivir Ther
|
2004
|
1.14
|
|
88
|
Impact of late presentation on the risk of death among HIV-infected people in France (2003-2009).
|
J Acquir Immune Defic Syndr
|
2013
|
1.14
|
|
89
|
New method for estimating HIV incidence and time from infection to diagnosis using HIV surveillance data: results for France.
|
AIDS
|
2011
|
1.13
|
|
90
|
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years.
|
Arch Intern Med
|
2010
|
1.12
|
|
91
|
The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.
|
AIDS
|
2012
|
1.11
|
|
92
|
Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.
|
Int J Epidemiol
|
2012
|
1.11
|
|
93
|
Evaluation of a peer support group therapy for HIV-infected adolescents.
|
AIDS
|
2005
|
1.11
|
|
94
|
Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study.
|
J Antimicrob Chemother
|
2013
|
1.10
|
|
95
|
Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113).
|
Antivir Ther
|
2008
|
1.10
|
|
96
|
Clinical progression rates by CD4 cell category before and after the initiation of combination antiretroviral therapy (cART).
|
Open AIDS J
|
2008
|
1.09
|
|
97
|
Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France.
|
J Antimicrob Chemother
|
2010
|
1.09
|
|
98
|
Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation.
|
Clin Infect Dis
|
2009
|
1.08
|
|
99
|
Opportunistic infections as causes of death in HIV-infected patients in the HAART era in France.
|
Scand J Infect Dis
|
2005
|
1.07
|
|
100
|
Is statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation.
|
AIDS
|
2015
|
1.06
|
|
101
|
Factors associated with late antiretroviral therapy initiation in Cameroon: a representative multilevel analysis.
|
J Antimicrob Chemother
|
2013
|
1.05
|
|
102
|
Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).
|
Antivir Ther
|
2003
|
1.04
|
|
103
|
Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study.
|
Antivir Ther
|
2009
|
1.04
|
|
104
|
A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control.
|
AIDS
|
2015
|
1.04
|
|
105
|
Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network.
|
Antivir Ther
|
2007
|
1.04
|
|
106
|
Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France.
|
AIDS
|
2009
|
1.04
|
|
107
|
Response to highly active antiretroviral therapy at 6 months and long-term disease progression in HIV-1 infection.
|
J Acquir Immune Defic Syndr
|
2005
|
1.04
|
|
108
|
Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression.
|
J Acquir Immune Defic Syndr
|
2009
|
1.04
|
|
109
|
Relationship between regulatory T cells and immune activation in human immunodeficiency virus-infected patients interrupting antiretroviral therapy.
|
PLoS One
|
2010
|
1.04
|
|
110
|
Limited impact of immunosuppression and HAART on the incidence of cervical squamous intraepithelial lesions in HIV-positive women.
|
Antivir Ther
|
2006
|
1.03
|
|
111
|
Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study.
|
BMC Infect Dis
|
2014
|
1.02
|
|
112
|
HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy.
|
Blood
|
2011
|
1.02
|
|
113
|
HIV-associated tuberculosis and immigration in a high-income country: incidence trends and risk factors in recent years.
|
AIDS
|
2010
|
1.01
|
|
114
|
The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study.
|
Int J Cancer
|
2011
|
1.00
|
|
115
|
Transcutaneous anti-influenza vaccination promotes both CD4 and CD8 T cell immune responses in humans.
|
J Immunol
|
2008
|
1.00
|
|
116
|
Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094).
|
Vaccine
|
2005
|
0.99
|
|
117
|
Impact of HIV infection on severity of imported malaria is restricted to patients with CD4 cell counts < 350 cells/microl.
|
AIDS
|
2009
|
0.99
|
|
118
|
Acute coronary syndrome in human immunodeficiency virus-infected patients: characteristics and 1 year prognosis.
|
Eur Heart J
|
2010
|
0.99
|
|
119
|
Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
|
Antimicrob Agents Chemother
|
2009
|
0.99
|
|
120
|
Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine.
|
AIDS
|
2011
|
0.98
|
|
121
|
A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir.
|
J Med Virol
|
2010
|
0.98
|
|
122
|
Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
|
J Med Virol
|
2004
|
0.97
|
|
123
|
Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
|
J Med Virol
|
2005
|
0.96
|
|
124
|
Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4).
|
Int J Epidemiol
|
2014
|
0.96
|
|
125
|
Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy.
|
AIDS
|
2010
|
0.95
|
|
126
|
Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial.
|
Antivir Ther
|
2002
|
0.95
|
|
127
|
NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients.
|
Eur J Immunol
|
2012
|
0.94
|
|
128
|
Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement.
|
J Clin Oncol
|
2006
|
0.94
|
|
129
|
Contraceptive use in HIV-positive women.
|
J Acquir Immune Defic Syndr
|
2004
|
0.93
|
|
130
|
Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial.
|
AIDS
|
2010
|
0.93
|
|
131
|
Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097).
|
AIDS
|
2004
|
0.93
|
|
132
|
β-Blocker use for patients with or at risk for coronary artery disease.
|
JAMA
|
2013
|
0.93
|
|
133
|
A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: the ANRS EP29 Lipostop Study.
|
Antivir Ther
|
2007
|
0.93
|
|
134
|
Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice.
|
Crit Rev Oncol Hematol
|
2008
|
0.93
|
|
135
|
Causes of death in HIV-infected women: persistent role of AIDS. The 'Mortalité 2000 & 2005' Surveys (ANRS EN19).
|
Int J Epidemiol
|
2009
|
0.93
|
|
136
|
Effects of type of smoking (pipe, cigars or cigarettes) on biological indices of tobacco exposure and toxicity.
|
Lung Cancer
|
2006
|
0.92
|
|
137
|
High rate of recurrence of cervical intraepithelial neoplasia after surgery in HIV-positive women.
|
J Acquir Immune Defic Syndr
|
2005
|
0.92
|
|
138
|
Yearly number of patients diagnosed with primary HIV-1 infection in France estimated by a capture-recapture approach.
|
AIDS
|
2006
|
0.92
|
|
139
|
Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial.
|
AIDS
|
2011
|
0.91
|
|
140
|
Wild type and H43Y variant of human TRIM5alpha show similar anti-human immunodeficiency virus type 1 activity both in vivo and in vitro.
|
Immunogenetics
|
2007
|
0.91
|
|
141
|
Impact of insertions in the HIV-1 p6 PTAPP region on the virological response to amprenavir.
|
Antivir Ther
|
2004
|
0.91
|
|
142
|
Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?
|
AIDS
|
2008
|
0.91
|
|
143
|
Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: results from the FHDH-ANRS CO4 cohort.
|
Clin Infect Dis
|
2013
|
0.91
|
|
144
|
Time to AIDS from 1992 to 1999 in HIV-1-infected subjects with known date of infection.
|
J Acquir Immune Defic Syndr
|
2002
|
0.91
|
|
145
|
Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial.
|
PLoS One
|
2010
|
0.91
|
|
146
|
Burden of HIV and hepatitis C co-infection: the changing epidemiology of hepatitis C in HIV-infected patients in France.
|
Liver Int
|
2014
|
0.90
|
|
147
|
Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.
|
Antivir Ther
|
2003
|
0.89
|
|
148
|
Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy.
|
AIDS
|
2006
|
0.89
|
|
149
|
Trends in post-infection CD4 cell counts and plasma HIV-1 RNA levels in HIV-1-infected patients in France between 1997 and 2005.
|
J Acquir Immune Defic Syndr
|
2009
|
0.89
|
|
150
|
Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir.
|
AIDS
|
2016
|
0.87
|
|
151
|
Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response.
|
J Infect Dis
|
2008
|
0.87
|
|
152
|
Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort.
|
AIDS
|
2014
|
0.87
|
|
153
|
Prevalence of low bone mineral density in men and women infected with human immunodeficiency virus 1 and a proposal for screening strategy.
|
J Clin Densitom
|
2012
|
0.86
|
|
154
|
Modeling the time course of CD4 T-lymphocyte counts according to the level of virologic rebound in HIV-1-infected patients on highly active antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2003
|
0.86
|
|
155
|
Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test.
|
J Am Coll Cardiol
|
2010
|
0.86
|
|
156
|
Risk of Kaposi sarcoma during the first months on combination antiretroviral therapy.
|
AIDS
|
2013
|
0.86
|
|
157
|
Distinct differentiation profiles of HIV-Gag and Nef-specific central memory CD8+ T cells associated with HLA-B57/5801 and virus control.
|
AIDS
|
2010
|
0.86
|
|
158
|
First-line highly active antiretroviral regimens in 2001-2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes.
|
Antivir Ther
|
2007
|
0.85
|
|
159
|
Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency.
|
Clin Infect Dis
|
2008
|
0.85
|
|
160
|
Bleeding complications in primary percutaneous coronary intervention of ST-elevation myocardial infarction in a radial center.
|
Catheter Cardiovasc Interv
|
2011
|
0.85
|
|
161
|
Influence of mother and infant zidovudine treatment duration on the age at which HIV infection can be detected by polymerase chain reaction in infants.
|
Antivir Ther
|
2004
|
0.85
|
|
162
|
Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.
|
J Antimicrob Chemother
|
2008
|
0.85
|
|
163
|
Prevalence of complete resistance to at least two classes of antiretroviral drugs in treated HIV-1-infected patients: a French nationwide study.
|
J Med Virol
|
2005
|
0.85
|
|
164
|
Surgical management of cervical intraepithelial neoplasia in HIV-infected women.
|
Eur J Obstet Gynecol Reprod Biol
|
2008
|
0.85
|
|
165
|
National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011.
|
J Antimicrob Chemother
|
2013
|
0.85
|
|
166
|
A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy.
|
HIV Clin Trials
|
2010
|
0.85
|
|
167
|
Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes.
|
J Infect Dis
|
2012
|
0.84
|
|
168
|
Looking Beyond the Cascade of HIV Care to End the AIDS Epidemic: Estimation of the Time Interval From HIV Infection to Viral Suppression.
|
J Acquir Immune Defic Syndr
|
2016
|
0.84
|
|
169
|
CD4+ T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4+ T-cell counts >200 cells/mm3.
|
Antivir Ther
|
2009
|
0.84
|
|
170
|
HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART.
|
AIDS
|
2007
|
0.84
|
|
171
|
Vitamin D supplementation is associated with reduced immune activation levels in HIV-1-infected patients on suppressive antiretroviral therapy.
|
AIDS
|
2014
|
0.84
|
|
172
|
IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy--results from the ANRS CO4 cohort.
|
J Antimicrob Chemother
|
2010
|
0.84
|
|
173
|
Better health-related quality of life after switching from a virologically effective regimen to a regimen containing efavirenz or nevirapine.
|
AIDS Care
|
2010
|
0.84
|
|
174
|
Characteristics of the env genes of HIV type 1 quasispecies in long-term nonprogressors with broadly neutralizing antibodies.
|
J Acquir Immune Defic Syndr
|
2008
|
0.83
|
|
175
|
Specific adaptive humoral response against a gp41 motif inhibits CD4 T-cell sensitivity to NK lysis during HIV-1 infection.
|
AIDS
|
2006
|
0.83
|
|
176
|
The unrecognised French BSE epidemic.
|
Vet Res
|
2004
|
0.83
|
|
177
|
Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
|
Antivir Ther
|
2006
|
0.83
|
|
178
|
Breast cancer among HIV infected individuals from the ONCOVIH study, in France: therapeutic implications.
|
Eur J Cancer
|
2012
|
0.83
|
|
179
|
Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia.
|
AIDS
|
2013
|
0.83
|
|
180
|
Bivariate longitudinal model for the analysis of the evolution of HIV RNA and CD4 cell count in HIV infection taking into account left censoring of HIV RNA measures.
|
J Biopharm Stat
|
2003
|
0.83
|
|
181
|
Increased cardiovascular risk in HIV infection: drugs, virus and immunity.
|
AIDS
|
2008
|
0.83
|
|
182
|
Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.
|
Clin Infect Dis
|
2015
|
0.83
|
|
183
|
T-cell activation positively correlates with cell-associated HIV-DNA level in viremic patients with primary or chronic HIV-1 infection.
|
AIDS
|
2014
|
0.83
|
|
184
|
Boosted protease inhibitor monotherapy as a maintenance strategy: an observational study.
|
AIDS
|
2012
|
0.82
|
|
185
|
Relative contributions of baseline patient characteristics and the choice of statistical methods to the variability of genotypic resistance scores: the example of didanosine.
|
J Antimicrob Chemother
|
2010
|
0.82
|
|
186
|
Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy.
|
Clin Infect Dis
|
2003
|
0.82
|
|
187
|
IL-2 therapy and thymic production of naive CD4 T cells in HIV-infected patients with severe CD4 lymphopenia.
|
AIDS
|
2003
|
0.82
|
|
188
|
Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe.
|
J Acquir Immune Defic Syndr
|
2012
|
0.81
|
|
189
|
Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial.
|
AIDS
|
2016
|
0.81
|
|
190
|
No influence of human herpesvirus 8 infection on the progression of HIV-1 infection in initially asymptomatic patients.
|
AIDS
|
2003
|
0.81
|
|
191
|
Estimating incidence of the French BSE infection using a joint analysis of both asymptomatic and clinical BSE surveillance data.
|
Math Biosci
|
2007
|
0.81
|
|
192
|
Altered heterochromatin organization after perinatal exposure to zidovudine.
|
Antivir Ther
|
2007
|
0.81
|
|
193
|
MHC-driven HIV-1 control on the long run is not systematically determined at early times post-HIV-1 infection.
|
AIDS
|
2013
|
0.81
|
|
194
|
Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study.
|
Clin Infect Dis
|
2016
|
0.79
|
|
195
|
High indinavir plasma concentrations in HIV-positive patients co-infected with hepatitis B or C virus treated with low doses of indinavir and ritonavir (400/100 mg twice a day) plus two nucleoside reverse transcriptase inhibitors.
|
AIDS
|
2003
|
0.79
|
|
196
|
Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120).
|
AIDS Res Hum Retroviruses
|
2012
|
0.79
|
|
197
|
Including pre-AIDS mortality in back-calculation model to estimate HIV prevalence in France, 2000.
|
Eur J Epidemiol
|
2006
|
0.79
|
|
198
|
Alterations of self-reactive antibody repertoires in HIV disease: an insight into the role of T cells in the selection of autoreactive B cells.
|
Immunol Lett
|
2005
|
0.79
|
|
199
|
Rosuvastatin Is Effective to Decrease CD8 T-Cell Activation Only in HIV-Infected Patients With High Residual T-Cell Activation Under Antiretroviral Therapy.
|
J Acquir Immune Defic Syndr
|
2016
|
0.79
|
|
200
|
Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets.
|
AIDS
|
2010
|
0.79
|
|
201
|
HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide.
|
J Antimicrob Chemother
|
2008
|
0.78
|
|
202
|
Early initiation of treatment for HIV infection.
|
Lancet
|
2010
|
0.78
|
|
203
|
[Non-AIDS-defining malignancies in HIV patients: clinical features and perspectives].
|
Bull Cancer
|
2006
|
0.78
|
|
204
|
Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial).
|
Antivir Ther
|
2003
|
0.78
|
|
205
|
Lack of regression of anal squamous intraepithelial lesions despite immune restoration under cART.
|
AIDS
|
2013
|
0.78
|
|
206
|
Evaluating therapeutic vaccines in patients infected with HIV.
|
Expert Rev Vaccines
|
2004
|
0.78
|
|
207
|
Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy.
|
Antimicrob Agents Chemother
|
2004
|
0.78
|
|
208
|
When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study.
|
J Acquir Immune Defic Syndr
|
2016
|
0.78
|
|
209
|
The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment.
|
AIDS
|
2016
|
0.77
|
|
210
|
Serious psychiatric outcome of subjects prenatally exposed to diethylstilboestrol in the E3N cohort study.
|
Psychol Med
|
2007
|
0.77
|
|
211
|
Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?
|
AIDS
|
2015
|
0.77
|
|
212
|
Quantitation of cytomegalovirus (CMV) DNA by real-time PCR for occurrence of CMV disease in HIV-infected patients receiving highly active antiretroviral therapy.
|
J Med Virol
|
2003
|
0.77
|
|
213
|
Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
|
AIDS
|
2009
|
0.77
|
|
214
|
A step ahead on the HIV collaboratory.
|
Science
|
2009
|
0.77
|
|
215
|
Interleukin 2 treatment does not modify hepatitis B or C replication in human immunodeficiency virus-infected patients: results from a randomized control trial.
|
Hepatology
|
2002
|
0.76
|
|
216
|
Characteristics of B-cell lymphomas in HIV/HCV-coinfected patients.
|
J Acquir Immune Defic Syndr
|
2014
|
0.76
|
|
217
|
Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
|
Br J Haematol
|
2002
|
0.76
|
|
218
|
Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia.
|
AIDS
|
2015
|
0.76
|
|
219
|
Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
|
Clin Infect Dis
|
2006
|
0.76
|
|
220
|
Effects of rosuvastatin versus pravastatin on low-density lipoprotein diameter in HIV-1-infected patients receiving ritonavir-boosted protease inhibitor.
|
AIDS
|
2012
|
0.76
|
|
221
|
Metabolic syndrome in a French cohort of patients with bipolar disorder: results from the FACE-BD cohort.
|
J Clin Psychiatry
|
2014
|
0.76
|
|
222
|
Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia.
|
AIDS
|
2016
|
0.75
|
|
223
|
Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals.
|
Medicine (Baltimore)
|
2016
|
0.75
|
|
224
|
Undiagnosed HIV prevalence in France: no evidence against universal HIV screening.
|
AIDS
|
2012
|
0.75
|
|
225
|
Determinants of low-density lipoprotein particle diameter during antiretroviral therapy including protease inhibitors in HIV-1-infected patients.
|
Antivir Ther
|
2012
|
0.75
|
|
226
|
Risk of HIV transmission under combined antiretroviral therapy: toward risk zero?
|
J Acquir Immune Defic Syndr
|
2015
|
0.75
|
|
227
|
[In Process Citation].
|
Therapie
|
2012
|
0.75
|
|
228
|
[Drug treatment of postmenopausal osteoporosis. What's New in 2006].
|
Presse Med
|
2006
|
0.75
|
|
229
|
BSE risk assessment as a basis for updating French screening policy.
|
Risk Anal
|
2007
|
0.75
|
|
230
|
Is impaired kidney function an independent predictor of the risk of myocardial infarction in HIV-infected individuals?
|
AIDS
|
2014
|
0.75
|
|
231
|
The cost of managing HIV infection in highly treatment-experienced, HIV-infected adults in France.
|
Pharmacoeconomics
|
2010
|
0.75
|
|
232
|
Interleukine-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4.
|
J Acquir Immune Defic Syndr
|
2009
|
0.75
|
|
233
|
Effect of immediate initiation of antiretroviral treatment in HIV-positive individuals aged 50 years or older.
|
J Acquir Immune Defic Syndr
|
2017
|
0.75
|
|
234
|
Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice.
|
J Antimicrob Chemother
|
2012
|
0.75
|
|
235
|
Influence of geographic origin, sex, and HIV transmission group on the outcome of first-line combined antiretroviral therapy in France.
|
AIDS
|
2016
|
0.75
|
|
236
|
Muscle and liver lactate metabolism in HAART-treated and naive HIV-infected patients: the MITOVIR study.
|
Antivir Ther
|
2005
|
0.75
|
|
237
|
Quantitative markers for cytomegalovirus disease in HIV-infected patients receiving highly active antiretroviral therapy.
|
AIDS
|
2003
|
0.75
|
|
238
|
Risk of cancers in HIV infection.
|
Enferm Infecc Microbiol Clin
|
2013
|
0.75
|
|
239
|
Modelling the budget impact of darunavir in the treatment of highly treatment-experienced, HIV-infected adults in France.
|
Pharmacoeconomics
|
2010
|
0.75
|
|
240
|
Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern cART era.
|
AIDS
|
2017
|
0.75
|
|
241
|
[Impact of new antiretroviral therapy in HIV infected patients with virologic failure].
|
Med Sci (Paris)
|
2012
|
0.75
|
|
242
|
[Is lung cancer screening by the helical scanner justified?].
|
Med Sci (Paris)
|
2007
|
0.75
|
|
243
|
How was the French BSE epidemic underestimated?
|
C R Biol
|
2006
|
0.75
|
|
244
|
[Towards a vaccine for HIV infection: role of the gp41 envelope protein].
|
Bull Acad Natl Med
|
2009
|
0.75
|
|
245
|
Dual nucleoside reverse transcriptase inhibitor therapy in the combination antiretroviral therapy era and predictors of discontinuation or switch to combination antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2008
|
0.75
|
|
246
|
On the comparison of artificial network and interpretation systems based on genotype resistance mutations in HIV-1-infected patients.
|
AIDS
|
2006
|
0.75
|
|
247
|
Cancers in elite controllers: appropriate follow-up is essential.
|
AIDS
|
2016
|
0.75
|
|
248
|
[Nursing surveillance during antitubercular drug treatment].
|
Soins
|
2006
|
0.75
|
|
249
|
[Cervical cancer: new testing strategies?].
|
Med Sci (Paris)
|
2008
|
0.75
|